Dr. Musa GAHRAMANOV

Former Head of the Invasive Cardiology Department of the Azerbaijan Cardiology Society

[Dr. Hardik Patel 🩺💉 @hardik4u24]

Which drug does what to the nephron & heart?

This single graphic shows the differences:

🟥 RAASi — eGFR dip, MACE↓
🟧 ARNI — NT-proBNP↓
🟩 SGLT2i — proteinuria↓
🟦 ns-MRA — fibrosis↓
🟪 GLP-1 RA — HFH↓

🔗 https://t.co/ruDprocbLm 🆕

#CardioRenal #HFpEF #HFrEF #CKD

[Pablo Corral MD @drpablocorral]

☝️Oral PCSK9 Inhibitors: A New Era in Lipid-Lowering Therapy?

👉Key takeaways:

1️⃣ Enlicitide (MK-0616) reduced LDL-C by ~56% in Phase III trials, with additional reductions in apoB, non-HDL-C, and Lp(a), showing efficacy comparable to injectable PCSK9 monoclonal antibodies.

2️⃣ Laroprovstat (AZD0780) achieved up to 50% LDL-C reduction and is currently advancing through Phase III development (AZURE Outcomes program), representing another highly promising oral PCSK9 inhibitor.

3️⃣ Other emerging oral agents—including DC371739, CVI-LM001, CiVi008, and the previously studied NNC0385-0434—highlight the growing diversity of strategies targeting the PCSK9 pathway and related lipid-regulating mechanisms.

👉The future may lie in simplified oral combination therapy: a statin + ezetimibe + oral PCSK9 inhibitor could potentially achieve 70–80% LDL-C reduction, bringing injectable-level efficacy into a convenient all-oral regimen.

👉 Ongoing cardiovascular outcome trials will determine whether these impressive lipid improvements translate into reductions in major cardiovascular events.

☝️Bottom line:
The next generation of lipid-lowering therapy may not be another injection—but a powerful triple oral combination capable of transforming cardiovascular prevention.

🔓🔗 https://t.co/gJyhZcIiph

@society_eas
@nationallipid
@ESC_Journals
@escardio

[Dr Luis Felipe Cabrera Vargas MD FACS @PipeCabreraV]

Step by step: the self locking knot! @TomVargheseJr @AmCollSurgeons @SWexner @pferrada1

[purushottam mittal @PurumittalDr]

Please guide what strategy should we use for this 75 yr frail lady with drug refractory class III angina

[Ahmed Bennis MD 🫀 @drbennisahmed]

Quadruple GDMT for HFrEF — start all 4 on Day 1.
ARNi → 28% mortality ↓
BB → 34% mortality ↓
MRA → 25% mortality ↓
SGLT2i → 17% mortality ↓
Together: 73% all-cause mortality RRR. NNT = 3.9. Median survival extended 7–11 years.

#HFrEF #GDMT

[Manual Of Medicine @ManualOMedicine]

@Ecgloverr @syamkumarmd @ALFIEEP1 @Hapa_EP @DaveRichley @AThomazAndrade @javadm20 @SergioPinski @ecgandrhythmRoe @ProfDConnelly @ECGEPSCADEVICE @Koichi16423232 AVRT

https://t.co/DFQxqYeXqO

[Harshi Peiris, Ph.D. @Neuroscope_mp]

BREAKING
🧬 Scientists just edited a gene in living humans — and LDL "bad" cholesterol dropped by 62%.

One injection.
One time. No daily pills.
Effects lasting 18 months.

This isn't science fiction.
It's a Phase 1b trial published in the NEJM this week.

Here's what just happened 🧵

[Tomas Gonzalez-Fernandez @TomasGF90]

New @TheTGFLab pre-print in BioRxiv! 🧬
In this paper led by Josh Graham we establish that not all #CRISPR delivery systems are created equal and that editing efficiency alone is insufficient for delivery system selection.
Check it out! ⬇️⬇️
https://t.co/HctkLohTYp

[오창명 @changmyung1981]

Here’s a tightened version optimized for scientific X/Twitter audiences with DOI integration and cleaner translational framing.

🧬 A major inflection point for cardiovascular CRISPR therapy.

The Phase 1 NEJM data for CTX310 suggests we are entering the era of in vivo “one-and-done” cardiometabolic gene editing.

CTX310, developed by CRISPR Therapeutics, uses lipid nanoparticle (LNP)-delivered CRISPR-Cas9 editing to permanently disrupt ANGPTL3 in hepatocytes.

Why ANGPTL3?

Human loss-of-function genetics have long shown that reduced ANGPTL3 activity is associated with:
📉 lower LDL-C
📉 lower triglycerides
📉 reduced ASCVD risk

Now we are seeing that biology translated directly into the clinic.

Reported Phase 1 outcomes:
✅ ~50% LDL-C reduction
✅ ~55% triglyceride reduction
✅ Durable ANGPTL3 suppression after a single infusion

This is bigger than another lipid-lowering drug.

For decades, cardiovascular prevention depended on chronic adherence:

- statins
- ezetimibe
- PCSK9 antibodies
- siRNA therapeutics

CTX310 represents a fundamentally different paradigm:
permanent genomic rewriting of hepatic lipid metabolism.

What makes this moment especially important is the broader convergence now happening across the field:

🧬 Verve → PCSK9 base editing
🧬 Intellia → KLKB1 editing
🧬 CRISPR Therapeutics → ANGPTL3 knockout

Together, these programs suggest CRISPR is transitioning from rare monogenic disease toward population-scale chronic disease intervention.

Of course, major questions remain:
⚠️ long-term off-target safety
⚠️ durability over decades
⚠️ immune responses
⚠️ retreatment feasibility
⚠️ ethical deployment in preventive medicine

But one thing is becoming increasingly clear:

The future of cardiometabolic medicine may not simply involve taking better drugs.

It may involve rewriting the risk architecture itself.

DOI:
10.1056/NEJMc2518635

Refs:
Kunimasa K. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025.

Bader J et al. Extracellular vesicles versus lipid nanoparticles for nucleic acid delivery. Adv Drug Deliv Rev. 2024.
DOI: 10.1016/j.addr.2024.115461

[Spor Rehberi @sagIikIiyasam]

Karın kaslarınız için 4 egzersiz

[Spor & Motivasyon @sporrmotivasyon]

3 haftada göbek yağını eritin.🔥💪

[GAİN @GainMedya]

"Geçmiş asla geçmemiş ve geçmeyecek olandır. Ben bunu anladığımda her şey çoktan geçmişti."

#Terapist afişi yayında! Terapist, Ocak'ta Gain'de! #GAİNdeNelerNelerVar 🎈

[chuu @lcews]

the true art of sewing 🪡🧵

[Interesting STEM @InterestingSTEM]

Erection Pump

Erection pumps, also known as vacuum pumps, are devices used to treat erectile dysfunction (ED) in men. These pumps work by creating a vacuum around the penis, which causes blood to flow into the tissue, resulting in an erection.

[JACC Journals @JACCJournals]

The RETRY protocol for radial artery occlusion recanalization, based on ultrasound-guided distal radial access and DCB angioplasty, is feasible, safe, and associated with excellent technical success and favorable short-term patency. https://t.co/EzP2NstK7F

[Dr Ihab Suliman @IhabFathiSulima]

What are the findings?

[Amitabh Yaduvanshi MD, DM, FACC, FSCAI @IntervnCardio]

1/8 🧵 Are beta-blockers still universally necessary after a heart attack if your heart function (LVEF ≥ 40%) is preserved?
A 2026 systematic review and meta-analysis of 4 major contemporary trials—encompassing 22,730 patients—re-evaluates this decades-old standard.
Let's dive in! 👇

[Jasmine Sethi @JasmineNephro]

🆕💥Newer CKD drugs

✅ARNI-Angiotension receptor/Neprilysin inhibitor

✅sodium glucose transporter 2 inhibitors (SGLT2i)

✅glucagon-like peptides-1 (GLP-1)
agonists

✅finerenone

@KIReports

https://t.co/TSCsIr3tBn

[Ahmed Bennis MD 🫀 @drbennisahmed]

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

https://t.co/ZUf9AOF2qR